Silexion Therapeutics Corp.

SLXNW

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0002022416


None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.2M
Warnings	short runway, thin data not computable: dilution, degenerate inputs, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through May 19, 2026 167 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.02 2026-10-22; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

Unless the context otherwise requires, in this "Business" section, the terms "we," "us" and "our" generally refer to: (i) for the period following the Closing of the Business Combination on August 15, 2024, Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company ("Silexion") and its consolidated subsidiaries, including Silexion Therapeutics Ltd., an Israeli company ("Silexion Israel"), through which our business is primarily conducted, and, (ii) with respect to all periods prior to and through the Closing of the Business Combination, Silexion Israel and its subsidiaries.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 19.9						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(21.7%)	(6.6%)	19.9	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 73.2					
Twelve-month failure probability	not computable	0.08%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(31.64)	(0.35)	81.5	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	2.41x	2.92x	65.0	829	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 2					
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.2 months
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-22 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(88.7%)	(2.2%)	3
Distance from 52-week high	(85.4%)	(28.7%)	6
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(2.35)	(0.19)	3

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$2.2M
Operating cash flow, four quarters	-$12.4M
Months of runway	2.2
Days since last periodic filing	80 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$43

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$11.9M	2025-12-31	2026-03-17	10-K	26-000953
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.8M	2025-12-31	2026-03-17	10-K	26-000953
3	assets	us-gaap:Assets	$7.2M	2025-12-31	2026-03-17	10-K	26-000953
4	assets	us-gaap:Assets	$2.9M	2024-12-31	2026-03-17	10-K	26-000953
5	current assets	us-gaap:AssetsCurrent	$6.6M	2025-12-31	2026-03-17	10-K	26-000953
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.8M	2025-12-31	2026-03-17	10-K	26-000953
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$55.2M	2025-12-31	2026-03-17	10-K	26-000953
8	operating income	us-gaap:OperatingIncomeLoss	-$11.6M	2025-12-31	2026-03-17	10-K	26-000953
9	book equity	us-gaap:StockholdersEquity	$2.6M	2025-12-31	2026-03-17	10-K	26-000953
10	liabilities	us-gaap:Liabilities	$4.6M	2025-12-31	2026-03-17	10-K	26-000953
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9,000	2025-12-31	2026-03-17	10-K	26-000953
12	depreciation amortization	us-gaap:Depreciation	$14,000	2025-12-31	2026-03-17	10-K	26-000953
13	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$11.9M	2025-12-31	2026-03-17	10-K	26-000953
14	income tax	us-gaap:IncomeTaxExpenseBenefit	$3,000	2025-12-31	2026-03-17	10-K	26-000953
15	current assets	us-gaap:AssetsCurrent	$2.2M	2024-12-31	2026-03-17	10-K	26-000953
16	current liabilities	us-gaap:LiabilitiesCurrent	$3.5M	2024-12-31	2026-03-17	10-K	26-000953

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.